Although previous systematic reviews and NMAs have highlighted the role of anti‐TNF drugs and IL inhibitors in the clinical remission or response of patients with Crohn's disease, the evidence is still controversial, especially regarding drug doses and routes of administration, and is often limited to a few biologics (adalimumab, natalizumab, vedolizumab, ustekinumab, certolizumab pegol, infliximab, risankizumab) [14, 15]. The gene discussed is TNF; the disease is Crohn disease.